Last $22.75 USD
Change Today 0.00 / 0.00%
Volume 0.0
GLPYY On Other Exchanges
Symbol
Exchange
EN Amsterdam
OTC US
OTC US
Frankfurt
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

galapagos nv-spon adr (GLPYY) Snapshot

Open
$22.50
Previous Close
$22.75
Day High
$22.75
Day Low
$22.50
52 Week High
03/13/14 - $23.86
52 Week Low
10/17/14 - $12.91
Market Cap
684.8M
Average Volume 10 Days
644.5
EPS TTM
--
Shares Outstanding
30.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GALAPAGOS NV-SPON ADR (GLPYY)

Related News

No related news articles were found.

galapagos nv-spon adr (GLPYY) Related Businessweek News

No Related Businessweek News Found

galapagos nv-spon adr (GLPYY) Details

Galapagos NV, a biotech company, discovers and develops small moleculesfor the treatment of cancer, immuno-inflammatory, osteoarthritis, rheumatoid arthritis, and cystic fibrosis diseases. The company’s products under development include GLPG0634, an orally-available, selective inhibitor of Janus kinase 1 that is in Phase IIB clinical trials for the treatment of rheumatoid arthritis (RA) and potentially other inflammatory diseases; and GLPG0778/555, an investigational compound, which is in Phase II studies for the treatment of lupus, ulcerative colitis, and psoriasis. It is also developing GSK2586184, which is in Phase II clinical trials for the treatment of immuno-inflammatory diseases; GLPG0974, an orally available small molecule that is in Phase IB clinical trials to treat neutrophil-driven inflammatory conditions, such as inflammatory bowel disease; and GLPG1205, a drug candidate that completed Phase I clinical trial for the treatment of inflammatory bowel disease. The company has strategic alliances with GlaxoSmithKline, Janssen Pharmaceutica NV, Servier, and AbbVie; and research collaboration agreement with Calchan Holdings Limited. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

810 Employees
Last Reported Date: 04/25/14
Founded in 1999

galapagos nv-spon adr (GLPYY) Top Compensated Officers

Co-Founder, Chief Executive Officer, Managing...
Total Annual Compensation: €740.1K
Compensation as of Fiscal Year 2013.

galapagos nv-spon adr (GLPYY) Key Developments

Galapagos NV Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 10:30 AM

Galapagos NV Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 10:30 AM. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Speakers: Andre Hoekema, Senior Vice President of Corporate Development and Member of Executive Committee.

Galapagos NV Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 03:30 PM

Galapagos NV Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 03:30 PM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States.

Galapagos Reports Positive Phase 1 Results for GLPG1690

Galapagos NV announced that GLPG1690, a first-in-class molecule for pulmonary disease, has demonstrated target engagement, a good safety profile, and favorable drug properties in a Phase 1 study. Galapagos is developing GLPG1690 within its alliance with Janssen Pharmaceutica NV. The aim of the Phase 1 study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single and multiple ascending doses of GLPG1690. The randomized, double-blind, placebo-controlled, single center study was conducted in 40 healthy volunteers in Belgium. In the first part of the study, single ascending doses were evaluated. In the second part, the new compound was administered daily for 14 days. GLPG1690 proved to be safe and well-tolerated over a wide dose range in healthy volunteers. Engagement of the thus far undisclosed novel target was confirmed using a relevant biomarker. GLPG1690 displayed a favorable pharmacokinetic and pharmacodynamic profile. The data shown in Phase 1 encourage Galapagos to explore a Phase 2 study design in pulmonary disease.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GLPYY:US $22.75 USD 0.00

GLPYY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GLPYY.
View Industry Companies
 

Industry Analysis

GLPYY

Industry Average

Valuation GLPYY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 2.2x
Price/Cash Flow 9.5x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALAPAGOS NV-SPON ADR, please visit www.glpg.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.